Bristol Myers Squibb (CELG-RI) Net Cash Flow (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Net Cash Flow of -$851.0 million for Q2 2026, down 152.92% year-over-year from $1.6 billion in Q2 2025, and down 44.97% quarter-over-quarter from -$587.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Net Cash Flow (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Net Cash Flow for 18 consecutive years, with -$851.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 152.92% year-over-year to -$851.0 million; the TTM figure through Jun 2026 stood at -$3.8 billion (down 161.9% YoY), while the FY2025 annual figure was -$324.0 million, up 68.7% from the prior year.
- Net Cash Flow declined to -$851.0 million in Q2 2026 per CELG-RI's latest filing, from -$587.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $3.9 billion in Q4 2023 and bottomed at -$5.5 billion in Q4 2025.
- Historically, Net Cash Flow has averaged -$311.4 million across 5 years, with a median of -$601.0 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 2768.97% — and 2024, when it surged 285.59%.
- Bristol Myers Squibb's Net Cash Flow stood at $1.3 billion in 2022, then soared by 204.24% to $3.9 billion in 2023, then sank by 32.84% to $2.6 billion in 2024, then slumped by 311.96% to -$5.5 billion in 2025, then jumped by 84.56% to -$851.0 million in 2026.
- Business Quant data shows CELG-RI's Net Cash Flow at -$851.0 million in Q2 2026, -$587.0 million in Q1 2026, and -$5.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -851.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -851.00 Mn |
| Jun 30, 2026 | -851.00 Mn |
| Mar 31, 2026 | -587.00 Mn |
| Mar 31, 2026 | -587.00 Mn |
| Dec 31, 2025 | -5.51 Bn |
| Dec 31, 2025 | -5.51 Bn |
| Sep 30, 2025 | 3.12 Bn |
| Sep 30, 2025 | 3.12 Bn |
| Jun 30, 2025 | 1.61 Bn |
| Jun 30, 2025 | 1.61 Bn |
| Mar 31, 2025 | 462.00 Mn |
| Mar 31, 2025 | 462.00 Mn |
| Dec 31, 2024 | 2.60 Bn |
| Dec 31, 2024 | 2.60 Bn |
| Sep 30, 2024 | 1.52 Bn |
| Sep 30, 2024 | 1.52 Bn |
| Jun 30, 2024 | -3.02 Bn |
| Jun 30, 2024 | -3.02 Bn |
| Mar 31, 2024 | -2.14 Bn |
| Mar 31, 2024 | -2.14 Bn |